About Celularity Inc. - Class A Common Stock (CELU)
Celularity Inc is a biotechnology company focused on developing innovative cell therapies and regenerative medicine solutions. The company harnesses the power of placental-derived cells and utilizes cutting-edge technology to create treatments aimed at addressing various health challenges, including cancer, autoimmune diseases, and age-related conditions. Celularity is committed to advancing the science of cell therapy and aims to improve patient outcomes through its unique approach to harnessing the immune system and addressing unmet medical needs. Through ongoing research and development, the company seeks to unlock the potential of cellular therapeutics and contribute to the future of medicine. Read More
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Company presents results from in vivo studies of PT-CD16VS, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells, in combination with various monoclonal antibodies
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday. The Dow traded up 0.66% to 38,403.91 while the NASDAQ rose 1.01% to 15,316.80. The S&P 500 also rose, gaining, 0.87% to 4,887.70.
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 0.5% on Thursday. The Dow traded up 0.23% to 38,238.99 while the NASDAQ rose 0.54% to 15,245.46. The S&P 500 also rose, gaining, 0.48% to 4,868.71.
